Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2025-12-25 @ 1:40 PM
NCT ID:
NCT04434092
Group ID:
EG001
Title:
Arm B: Eculizumab
Description:
Participants received loading doses of eculizumab 600 mg IV on Days 1, 8, 15, and 22, followed by maintenance doses of 900 mg IV on Day 29 and every 2 weeks (Q2W) thereafter up to Week 24 in the primary treatment period. Participants who switched to crovalimab received crovalimab as an IV loading dose of 1000 mg (if body weight was between 40 kg to \<100 kg) or 1500 mg (if body weight was \>=100kg) on Week 25 Day 1, 340 mg SC on Week 25 Day 2, then 340 mg SC QW on Weeks 26, 27, 28, followed by crovalimab maintenance dose of 680 mg SC (if body weight was between 40 kg to \<100 kg) or 1020 mg SC (if body weight was \>=100kg) on Week 29 and Q4W thereafter up to a maximum of 5 years in the extension treatment period.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
14
Serious Number At Risk:
69
Other Number Affected:
55
Other Number At Risk:
69
Study:
NCT04434092
Results Section:
NCT04434092
Adverse Events Module:
NCT04434092